Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 14/20 | 1.00 |
| ▸ | KDR | P35968 | 14/20 | 1.00 |
| ▸ | SRC | P12931 | 13/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 13/20 | 1.00 |
| ▸ | EGFR | P00533 | 3/20 | 0.80 |
| ▸ | AURKA | O14965 | 5/20 | 0.77 |
| ▸ | FYN | P06241 | 2/20 | 0.63 |
| ▸ | YES1 | P07947 | 2/20 | 0.63 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6405603 | 1.00 | FGFR1 (1.00) | FGFR1KDRSRCPDGFRBEGFR | |
| SCHEMBL6700644 | 0.99 | FGFR1 (0.98) | FGFR1KDRSRCPDGFRBEGFR | |
| SCHEMBL6701692 | 0.92 | SRC (0.84) | FGFR1KDRSRCPDGFRBEGFR | |
| SCHEMBL6695171 | 0.92 | KDR (0.84) | FGFR1KDRSRCPDGFRBEGFR | |
| SCHEMBL6394654 | 0.89 | SRC (0.80) | FGFR1KDRSRCPDGFRBEGFR | |
| SCHEMBL6390920 | 0.89 | SRC (0.80) | FGFR1KDRSRCPDGFRBEGFR | |
| SCHEMBL6394656 | 0.89 | SRC (0.80) | FGFR1KDRSRCPDGFRBEGFR | |
| SCHEMBL6390915 | 0.89 | SRC (0.80) | FGFR1KDRSRCPDGFRBEGFR | |
| SCHEMBL6698545 | 0.88 | SRC (0.79) | FGFR1KDRSRCPDGFRBEGFR | |
| SCHEMBL6696887 | 0.88 | SRC (0.79) | FGFR1KDRSRCPDGFRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067531-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | SUGEN, INC. | 2004-04-08 | — | — | US | claimed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | claimed |
| EP-2020408-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | Sugen, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20080125362-A1 | Method of screening compound preventing cells from infection with Hepatitis C virus (HCV) | JAPAN TOBACCO INC. (JP) | 2008-05-29 | — | — | US | disclosed |
| US-20080125362-A1 | Method of screening compound preventing cells from infection with Hepatitis C virus (HCV) | JAPAN TOBACCO INC. (JP) | 2008-05-29 | — | — | US | disclosed |
| US-6878733-B1 | Formulations for pharmaceutical agents ionizable as free acids or free bases | SUGEN, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040067531-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | SUGEN, INC. | 2004-04-08 | — | — | US | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
| EP-1233943-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | Sugen, Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001037820-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | SUGEN, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| WO-2000008202-A9 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067531-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | ABL1, LCK, PNCK | FGFR1 985/4885KDR 634/4885SRC 11/4885 |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | FGFR1 2701/4885KDR 1617/4885SRC 260/4885 |
| US-20080125362-A1 | Method of screening compound preventing cells from infection with Hepatitis C virus (HCV) | HAVCR2, FGFR1, FGFR2 | FGFR1 2/4885KDR 566/4885SRC 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.